Before Novartis! Skyrizi head to head phase 3 study reached the end point

Fan Dongdong announced on January 14 that his new anti-inflammatory drug skyrizi (risankizumab) defeated Novartis cosentityx (secukinumab) in the head-to-head phase 3 clinical research (nct03478787) in the treatment of plaque psoriasis to reach the primary end point and all secondary end points This is a multicenter, randomized, open label, positive drug control phase 3 study in adult patients with moderate to severe plaque psoriasis to assess the efficacy and safety of skyrizi and cosentyx The results showed that 87% of skyrizi treated patients reached pasi90 (psoriasis area and severity index improved by at least 90% compared with baseline), and 57% of cosentityx treated patients reached this standard (P < 0.001), reaching the main end point of pasi90 superiority The study also reached the primary non inferiority end point of pasi90 at week 16: 74% in the skyrizi group and 66% in the cosentyx group In addition, skyrizi also showed superiority in all secondary endpoints including pasi100, PASI75 and spga0 / 1 at week 52 (P < 0.001) "Such head-to-head trial data is essential to help patients and their doctors make informed treatment decisions," said Michael Severino, President of Aberdeen Skyrizi is a kind of interleukin-23 (IL-23) inhibitor Its active component is risankizumab IL-23 is a kind of cytokine, which is considered to play a key role in many chronic immune diseases, including psoriasis and inflammation Skyrizi selectively blocks the immune inflammatory mediator IL-23 in vivo by specifically targeting il-23p19 subunit, so as to treat related diseases The drug was originally developed by bringer Ingelheim, and in February 2016, eberway paid a $600 million advance payment to obtain the global commercial rights of the drug In April 2019, skyrizi was approved by FDA for use in the treatment of adult patients with moderate to severe plaque psoriasis suitable for systematic therapy or phototherapy Skyrizi is considered to be one of the key products supporting the performance of Aberdeen's "post repair Merlot era" Currently, the drug is being evaluated for treatment of a variety of immune and inflammatory diseases Skyrizi is entering a very crowded market and will compete with a number of biological agents, including Novartis cosentix, Lilly taltz, Valeant siliq, Johnson & Johnson tremfya and sun pharmaceutical ilumya Among them, tremfya and ilumya are also biotherapeutics that selectively target IL-23 Despite the number of competitors, the industry is still very optimistic about skyrizi's business prospects, and evaluatepharma predicted that the annual sales of the drug in 2024 would reach 2.2 billion US dollars Navin Jacob, an analyst at UBS, said that so far skyrizi has surpassed cosentix and tremfya in terms of number of listings, and that Alberto's product line supply capacity can meet future growth Skyrizi's growing demand is sure to give Alberto hope as the company nears the completion of a $63 billion merger with Elgin Although the large-scale merger is expected to create the world's fourth largest pharmaceutical manufacturer, there are still disadvantages The outside world pays great attention to the development of the integrated medical and beauty business of Erjian Earlier this month, Aberdeen announced that it would create a separate division to take charge of Elkem's medical and beauty products, while integrating higher income products such as Botox and the antipsychotic vraylar into a broader business The EU also proposed approval conditions for the merger of the two companies, requiring the two companies to divest brazikumab, iljian's IL-23 inhibitor The European Union says the drug clashes with Irvine's risankizumab and the cystic fibrosis drug zenprep, and Elgin has agreed to divest brazikumab Adorable adorable